Corpus Intelligence IC Memo — CLEARSKY REHAB HOSPITAL OF RIO RANCH 2026-04-26 13:36 UTC
IC Memo — CLEARSKY REHAB HOSPITAL OF RIO RANCH
Investment Committee Memorandum | NM | 36 beds | Grade C | EBITDA uplift $961K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CLEARSKY REHAB HOSPITAL OF RIO RANCH

CCN 323033 | nan, NM | 36 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

CLEARSKY REHAB HOSPITAL OF RIO RANCH is a 36-bed community hospital in nan, NM with $13.0M in net patient revenue and a 8.6% operating margin. The hospital serves a payer mix of 54.9% Medicare, 0.0% Medicaid, and 45.1% commercial.

Thesis: Turnaround. Our ML models identify $961K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 8.6% to 16.0% (+738bps).

Net Revenue HCRIS$13.0M
Current EBITDA COMPUTED$1.1M
Operating Margin COMPUTED8.6%
Occupancy HCRIS66.1%
Revenue / Bed COMPUTED$362K
Net-to-Gross HCRIS68.3%
Distress Probability MLnan%

2. Market Context & Competitive Position

55
NM Hospitals
-2.7%
State Median Margin
32
Comparable Hospitals

NM has 55 Medicare-certified hospitals with a median operating margin of -2.7%. The target's margin of 8.6% places it above the state median. Among 32 size-comparable peers (18-72 beds), the median margin is -3.2%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (18-72), prioritizing same-state peers. 32 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CLEARSKY REHAB HOSPITAL OF RIO (Target)NM36$13.0M8.6%
GERALD CHAMPION REGIONAL MEDICNM66$245.9M-11.6%
NOR-LEA HOSPITALNM25$131.5M0.9%
UNM SANDOVAL REGIONAL MEDICAL NM60$104.5M-11.9%
CARLSBAD MEDICAL CENTERNM53$97.1M19.9%
SANTA FE MEDICAL CENTERNM36$95.0M-26.5%
ESPANOLA HOSPITALNM70$84.1M-2.3%
GILA REGIONAL MEDICAL CENTERNM25$83.6M-3.6%
HOLY CROSS HOSPITALNM25$72.9M-20.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $961K (738bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$274K+210bp18mo
Cost to Collect4.5%2.5%$261K+200bp12mo
Denial Rate Reduction12.0%6.5%$259K+199bp12mo
A/R Days Reduction5200.0%3800.0%$159K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+7bp6mo

5. EBITDA Bridge

Net Collection Rate
$274K
Cost to Collect
$261K
Denial Rate Reduction
$259K
A/R Days Reduction
$159K
Clean Claim Rate
$10K
Total EBITDA Uplift$961K
Current EBITDA$1.1M
+ RCM Uplift+$961K
Pro Forma EBITDA$2.1M
Current Margin8.6%
Pro Forma Margin16.0%
WC Released (1x)$500K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$1.7M$17.0M9.87x58.1%
Base (11x exit)10.0x11.0x$1.7M$19.2M11.19x62.1%
Bull Case9.0x11.0x$1.5M$23.0M14.84x71.5%
Bull (12x exit)9.0x12.0x$1.5M$25.5M16.48x75.1%
Bear Case11.0x10.0x$1.9M$11.6M6.14x43.8%
Bear (11x exit)11.0x11.0x$1.9M$13.4M7.08x47.9%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 32 hospitals with 18-72 beds
  • Same-state prioritization (n=33)
  • Comp margins: P25=-21.3% / P50=-3.2% / P75=6.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.